SavedAdd your journal

Journals / Acta Medica / 2019 / Cilt: 50 - Sayı: 4

The Difference in Clinical and Prognostic Features Between De Novo and Recurrent Her2-Positive Metastatic Breast Cancer Patients

Yusuf ACIKGOZ
Yakup ERGÜN
Gökhan UÇAR
Merve DİRİKOÇ
Doğan UNCU
Pages
14–19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence of metastasis at the time of diagnosis or during follow-up did not change response to treatments

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: There are different data in the literature about the consequences of the development of metastasis as de novo or recurrent.
📊
Key Findings & Data:In this study, we retrospectively investigated the clinicopathologic and prognostic characteristics of HER-2 positive de novo and recurrent metastatic breast cancer patients.
💡
Conclusion & Impact:The presence of metastasis at the time of diagnosis or during follow-up did not change response to treatments
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: There are different data in the literature about the consequences of the development of metastasis as de novo or recurrent. In this study, we retrospectively investigated the clinicopathologic and prognostic characteristics of HER-2 positive de novo and recurrent metastatic breast cancer patients. Material and Methods: The data of patients admitted to our clinic between 1996- 2017 were analysed retrospectively. The baseline features, treatments and survival data were recorded. Recurrent metastatic patients were further categorized as disease free interval 24 months. The features of two groups were analysed by Pearson chi-square test. Survival were calculated by using the Kaplan-Meier method with the Long-rank test. p 24 months (p=0.135). Conclusion: Our study showed that baseline features of patients with de novo HER2 positive MBC and recurrent HER-2 positive metastatic breast cancer did not differ from each other. The presence of metastasis at the time of diagnosis or during follow-up did not change response to treatments

🔖

Cite This Article

ACIKGOZ, Y., ERGÜN, Y., UÇAR, G., DİRİKOÇ, M., UNCU, D. (2019). The Difference in Clinical and Prognostic Features Between De Novo and Recurrent Her2-Positive Metastatic Breast Cancer Patients. Acta Medica, Cilt: 50 - Sayı: 4, 14–19. https://ajindex.com/articles/143125

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. National Cancer Institute. Surveillance, Epidemiology, and Endb Results Program. SEER Stat Fact Sheets: Breast Cancer. https://seer.cancer.gov/statfacts/html/breast. html. Published 2018. Accessed
  2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Common Cancer Sites. https://seer.cancer.gov/statfacts/html/common.html. Published 2018. Accessed
  3. Engel-Nitz NM, Hao Y, Becker LK, et al. Costs and mortality of recurrent versus de novo hormone receptor-positive/ HER2(-) metastatic breast cancer. Journal of Comparative Effectiveness Research 2015; 4(4): 303-14
  4. Yamamura JUN, Kamigaki S, Fujita J, et al. The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptorpositive, HER2-negative Breast Cancer. In Vivo 2018; 32(2): 353-58
  5. Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1998; 16(7): 2401-08
  6. Dawood S, Broglio K, Ensor J, et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology 2010; 21(11): 2169-74
  7. Yardley DA, Kaufman PA, Brufsky A, et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment 2014; 145(3): 725-34
  8. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? British Journal of Cancer 2015; 112(9): 1445-51
  9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology 2010; 17(6): 1471-74
  10. Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26(30): 4891-98
  11. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004; 100(1): 44-52
  12. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in su